KR890701605A
(ko)
*
|
1987-07-04 |
1989-12-21 |
원본미기재 |
Dna 서열, 재조합 dna 분자 및 용해성 t4 단백질의 제조방법
|
IL87902A0
(en)
*
|
1987-10-08 |
1989-03-31 |
Dana Farber Cancer Inst Inc |
Soluble human cd4 fragments and applications thereof
|
US6004781A
(en)
*
|
1988-01-22 |
1999-12-21 |
The General Hospital Corporation |
Nucleic acid encoding Ig-CD4 fusion proteins
|
PT89484B
(pt)
*
|
1988-01-22 |
1994-03-31 |
Gen Hospital Corp |
Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
|
GB8824869D0
(en)
*
|
1988-10-24 |
1988-11-30 |
Stevenson G T |
Synthetic antibody
|
US5681566A
(en)
*
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
WO1990010015A1
(en)
*
|
1989-02-23 |
1990-09-07 |
Seragen, Inc. |
Chimeric toxin
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6267964B1
(en)
|
1989-08-01 |
2001-07-31 |
Affibody Technology Sweden Ab |
Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
|
FR2650598B1
(fr)
*
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
AU648041B2
(en)
*
|
1989-08-23 |
1994-04-14 |
General Hospital Corporation, The |
Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
US5945397A
(en)
*
|
1989-09-05 |
1999-08-31 |
Immunex Corporation |
Purified p75 (type II) tumor necrosis factor receptor polypeptides
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
US5395760A
(en)
*
|
1989-09-05 |
1995-03-07 |
Immunex Corporation |
DNA encoding tumor necrosis factor-α and -β receptors
|
EP1132471A3
(de)
*
|
1989-09-12 |
2001-11-28 |
F. Hoffmann-La Roche Ag |
TNF-bindende Proteine
|
US5767072A
(en)
*
|
1989-09-14 |
1998-06-16 |
Board Of Regents, The University Of Texas System |
Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections
|
JPH05502218A
(ja)
*
|
1989-09-14 |
1993-04-22 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
治療用組成物;hiv感染の治療方法
|
US5116944A
(en)
*
|
1989-12-29 |
1992-05-26 |
Neorx Corporation |
Conjugates having improved characteristics for in vivo administration
|
WO1991012021A2
(en)
*
|
1990-02-13 |
1991-08-22 |
Oxford Virology Plc |
Therapeutic agents, and intermediates for the synthesis thereof
|
US5498538A
(en)
*
|
1990-02-15 |
1996-03-12 |
The University Of North Carolina At Chapel Hill |
Totally synthetic affinity reagents
|
US5614612A
(en)
*
|
1990-03-09 |
1997-03-25 |
Haigwood; Nancy L. |
Purified gp120 compositions retaining natural conformation
|
US6641809B1
(en)
*
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
US5750371A
(en)
*
|
1990-04-27 |
1998-05-12 |
Takeda Chemical Industries Ltd |
Water-soluble mutein of FGF receptor, DNA and production thereof
|
AT396939B
(de)
*
|
1990-05-29 |
1993-12-27 |
Alois Dipl Ing Dr Jungbauer |
Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
|
US5349053A
(en)
*
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
ES2171392T3
(es)
*
|
1990-08-29 |
2002-09-16 |
Ct Hospitalier Regional De Nan |
Poliligandos de proteina unidos a un nucleo de proteina estable.
|
US5650150A
(en)
*
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
DE4037837A1
(de)
*
|
1990-11-28 |
1992-06-04 |
Behringwerke Ag |
Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
|
ATE145428T1
(de)
*
|
1990-12-14 |
1996-12-15 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
WO1992013559A1
(en)
*
|
1991-02-08 |
1992-08-20 |
Progenics Pharmaceuticals, Inc. |
CD4-GAMMA1 AND CD4-IgG1 CHIMERAS
|
US7070991B2
(en)
*
|
1991-02-08 |
2006-07-04 |
Progenics Pharmaceuticals, Inc. |
Cells expressing a CD4-IgG2 chimeric heterotetramer
|
AU660662B2
(en)
*
|
1991-02-08 |
1995-07-06 |
Progenics Pharmaceuticals, Inc. |
CD4-gamma2 and CD4-IgG2 chimeras
|
US5234905A
(en)
*
|
1991-02-22 |
1993-08-10 |
University Of Colorado Foundation, Inc. |
Soluble CD4 molecules modified to prolong circulating half-life
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
US6753162B1
(en)
|
1991-03-07 |
2004-06-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5851828A
(en)
|
1991-03-07 |
1998-12-22 |
The General Hospital Corporation |
Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
|
US5912170A
(en)
|
1991-03-07 |
1999-06-15 |
The General Hospital Corporation |
Redirection of cellular immunity by protein-tyrosine kinase chimeras
|
US6004811A
(en)
*
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
US5843728A
(en)
*
|
1991-03-07 |
1998-12-01 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
ATE193724T1
(de)
*
|
1991-03-12 |
2000-06-15 |
Biogen Inc |
Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
|
MX9203138A
(es)
*
|
1991-03-12 |
1992-09-01 |
Biogen Inc |
Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
|
US5212075A
(en)
*
|
1991-04-15 |
1993-05-18 |
The Regents Of The University Of California |
Compositions and methods for introducing effectors to pathogens and cells
|
ATE170559T1
(de)
*
|
1991-05-31 |
1998-09-15 |
Genentech Inc |
Behandlung der hiv-assoziierten immun- thrombopenie purpura
|
US5891841A
(en)
*
|
1991-06-11 |
1999-04-06 |
The Center For Blood Research, Inc. |
Methods of using intercellular adhesion molecule-3 (ICAM-3), antibodies thereto, and soluble fragments thereof
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
US5623053A
(en)
*
|
1992-01-10 |
1997-04-22 |
California Institute Of Technology |
Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
|
JP3616090B2
(ja)
*
|
1992-01-27 |
2005-02-02 |
イコス コーポレイション |
細胞間接着分子関連タンパク質
|
US5753502A
(en)
*
|
1993-08-05 |
1998-05-19 |
Icos Corporation |
Neuron-specific ICAM-4 promoter
|
US5532127A
(en)
*
|
1992-01-27 |
1996-07-02 |
Icos Corporation |
Assay for 1-CAM related protein expression
|
US5869262A
(en)
*
|
1992-01-27 |
1999-02-09 |
Icos Corporation |
Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
|
US5700658A
(en)
*
|
1992-01-27 |
1997-12-23 |
Icos Corporation |
ICAM-4 materials and methods
|
US5773293A
(en)
*
|
1992-01-27 |
1998-06-30 |
Icos Corporation |
Anti-ICAM-4 antibodies and hybridomas
|
US5852170A
(en)
*
|
1992-01-27 |
1998-12-22 |
Icos Corporation |
ICAM-4 materials and methods
|
US6153395A
(en)
*
|
1992-01-27 |
2000-11-28 |
Icos Corporation |
ICAM-related protein
|
US5837822A
(en)
*
|
1992-01-27 |
1998-11-17 |
Icos Corporation |
Humanized antibodies specific for ICAM related protein
|
US5989843A
(en)
*
|
1992-01-27 |
1999-11-23 |
Icos Corporation |
Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
|
US5702917A
(en)
*
|
1992-01-27 |
1997-12-30 |
Icos Corporation |
Polynucleotides encoding human ICAM-4
|
US6818743B1
(en)
|
1992-01-27 |
2004-11-16 |
Icos Corporation |
I-CAM related protein
|
US6100383A
(en)
*
|
1992-01-27 |
2000-08-08 |
Icos Corporation |
Fusion proteins comprising ICAM-R polypeptides and immunoglobulin constant regions
|
US5525487A
(en)
*
|
1992-01-27 |
1996-06-11 |
Icos Corporation |
DNA encoding I-CAM related protein
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
WO1993018160A1
(en)
*
|
1992-03-11 |
1993-09-16 |
Kenneth Francis Prendergast |
Anti-viral fusion peptides
|
GB9219562D0
(en)
|
1992-03-11 |
1992-10-28 |
Prendergast Kennet F |
Anti-viral peptides
|
JPH0640945A
(ja)
*
|
1992-07-23 |
1994-02-15 |
Kureha Chem Ind Co Ltd |
Fcフラグメント結合抗腫瘍剤
|
EP0664710A4
(de)
*
|
1992-08-07 |
1998-09-30 |
Progenics Pharm Inc |
IMMUNOKONJUGATE BESTEHEND AUS EINEM NICHT-PEPTIDYLEN TEIL UND EINEM CD4-GAMMA2- ODER CD4-IgG2 TEIL, UND VERWENDUNGEN DAVON.
|
AU5098393A
(en)
*
|
1992-08-14 |
1994-03-15 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Recombinant toxin with increased half-life
|
DE4228839A1
(de)
|
1992-08-29 |
1994-03-03 |
Behringwerke Ag |
Verfahren zum Nachweis und zur Bestimmung von Mediatoren
|
WO1994006469A1
(en)
*
|
1992-09-18 |
1994-03-31 |
La Jolla Institute For Allergy And Immunology |
Hiv fusion polypeptide
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
ZA955642B
(en)
*
|
1994-07-07 |
1997-05-06 |
Ortho Pharma Corp |
Lyophilized imaging agent formulation
|
US5910481A
(en)
*
|
1995-11-13 |
1999-06-08 |
Immuno Ag |
Hybrid proteins with modified activity
|
US5723125A
(en)
*
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
JP2001508642A
(ja)
*
|
1996-02-12 |
2001-07-03 |
セダーズ―シナイ メディカル センター |
ビタミンd応答エレメント結合タンパク質
|
EP0904366A1
(de)
|
1996-04-01 |
1999-03-31 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptiden
|
US6342586B1
(en)
|
1996-06-10 |
2002-01-29 |
Progenics Pharmaceuticals, Inc. |
Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
|
DE69732711T2
(de)
|
1996-07-12 |
2006-03-16 |
Genentech, Inc., South San Francisco |
Gamma-heregulin
|
WO1998002540A1
(en)
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
IL132560A0
(en)
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
DE69838249T3
(de)
|
1997-05-15 |
2012-01-19 |
Genentech, Inc. |
Anti-apo-2 antikörper
|
EP1003856A1
(de)
|
1997-06-05 |
2000-05-31 |
Board of Regents, The University of Texas System |
Apaf-1, menschluches ced-4 homolog, ein aktivator von caspase-3
|
CA2293740A1
(en)
|
1997-06-18 |
1998-12-23 |
Genentech, Inc. |
Apo-2dcr, a tnf-related receptor
|
EP0893507A1
(de)
*
|
1997-07-25 |
1999-01-27 |
Institut Gustave Roussy |
Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
EP1088084B1
(de)
|
1998-06-15 |
2006-09-13 |
GTC Biotherapeutics, Inc. |
Erythropoietin-analog-menschliches serum-albumin fusionsprotein
|
JP2002520053A
(ja)
|
1998-07-15 |
2002-07-09 |
ジェネンテック・インコーポレーテッド |
凝固因子fvii/fviiaに対する向上した親和性を持つ組織因子タンパク質変異体
|
WO2000039303A2
(en)
|
1998-12-31 |
2000-07-06 |
Chiron Corporation |
Modified hiv env polypeptides
|
EP1141313A2
(de)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Verbesserte exprimierung von hiv polypeptiden und herstellung von virusähnliche partikeln
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
AU2487300A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
WO2000046380A2
(en)
|
1999-02-08 |
2000-08-10 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
CA2380331C
(en)
|
1999-08-09 |
2012-11-20 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
JP5179689B2
(ja)
|
2000-02-11 |
2013-04-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗体ベース融合タンパク質の循環系内半減期の増強
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR20030036835A
(ko)
|
2000-09-26 |
2003-05-09 |
제넨테크, 인크. |
Ige 수용체 길항제
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
CA2446087C
(en)
|
2001-05-03 |
2013-06-18 |
Stephen D. Gillies |
Recombinant tumor specific antibody and use thereof
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
CA2454618C
(en)
|
2001-07-24 |
2012-04-03 |
Biogen Idec Ma, Inc. |
Methods for treating or preventing sclerotic disorders using cd2-binding agents
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
MXPA04001804A
(es)
|
2001-08-30 |
2005-03-07 |
Biorexis Pharmaceutical Corp |
Proteinas de fusion de transferrina modificada.
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
WO2003020876A2
(en)
|
2001-08-31 |
2003-03-13 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
EP1454138B1
(de)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokine mit modulierter selektivität
|
EP2261250B1
(de)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin Fusionsproteine
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20070071744A1
(en)
|
2002-06-07 |
2007-03-29 |
Gotz Munch |
Agents which bind to epitopes of glycoprotein VI
|
US7531178B2
(en)
|
2002-06-07 |
2009-05-12 |
Trigen Gmbh |
Immunoadhesin comprising a glycoprotein VI domain
|
EP1369128A1
(de)
|
2002-06-07 |
2003-12-10 |
Procorde GmbH |
Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
|
ATE471946T1
(de)
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
EP2385069A3
(de)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
|
BRPI0418286A
(pt)
|
2003-12-30 |
2007-05-02 |
Merck Patent Gmbh |
proteìnas de fusão de il-7
|
CA2552590A1
(en)
|
2004-01-05 |
2005-07-21 |
Emd Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
ES2330860T3
(es)
|
2004-01-22 |
2009-12-16 |
Merck Patent Gmbh |
Anticuerpos anticancerosos con fijacion del complemento reducida.
|
HUE027902T2
(en)
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
WO2005115436A1
(en)
|
2004-05-07 |
2005-12-08 |
Astellas Us Llc |
Soluble lfa-3 polypeptide for treating viral disorders
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
WO2006108455A1
(en)
|
2004-11-02 |
2006-10-19 |
Ares Trading S.A. |
Serum-free cell culture medium for mammalian cells
|
US8273553B2
(en)
|
2004-11-02 |
2012-09-25 |
Ares Trading S.A. |
Production of growth hormone in serum-free cell culture medium for mammalian cells
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP2332985A3
(de)
|
2004-11-12 |
2012-01-25 |
Xencor, Inc. |
Fc-Varianten mit modifizierter Bindung an fcrn
|
EP1931709B1
(de)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc-varianten mit optimierten rezeptorbindungseigenschaften
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
CA2635623C
(en)
|
2005-12-30 |
2015-02-17 |
Michael Super |
Anti-cd19 antibodies with reduced immunogenicity
|
DK1966238T3
(da)
|
2005-12-30 |
2012-07-16 |
Merck Patent Gmbh |
INTERLEUKIN-12P40-varianter med forbedret stabilitet
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
EP2067041A2
(de)
|
2006-10-03 |
2009-06-10 |
Biogen Idec MA, Inc. |
Biomarker und testreihen zur behandlung von krebs
|
CN101998965B
(zh)
|
2007-11-01 |
2014-03-12 |
安斯泰来制药有限公司 |
免疫抑制性多肽与核酸
|
CA2960659C
(en)
|
2007-11-09 |
2021-07-13 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
SI2235059T1
(sl)
|
2007-12-26 |
2015-06-30 |
Xencor, Inc. |
Fc variante s spremenjeno vezjo na fcrn
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
SG175233A1
(en)
|
2009-04-22 |
2011-11-28 |
Merck Patent Gmbh |
Antibody fusion proteins with modified fcrn binding sites
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
CN107208076A
(zh)
*
|
2014-10-17 |
2017-09-26 |
科达制药 |
丁酰胆碱酯酶两性离子聚合物缀合物
|
WO2017055522A1
(en)
|
2015-09-29 |
2017-04-06 |
Academisch Medisch Centrum |
Stabilized env proteins of hiv
|
CA3010056A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
EP4041312A4
(de)
|
2019-10-10 |
2023-12-20 |
Kodiak Sciences Inc. |
Verfahren zur behandlung einer augenstörung
|